The rising cancer incidence rate in China poses a substantial public health concern,
although there have been remarkable improvements in the country's cancer mortality and …

Over the past two decades, China has introduced significant changes to drug regulations
through regulatory innovations to accelerate drug review and approvals, keeping in line with …

Access to anticancer drugs has been a critical health issue in China for many years. We
retrospectively analyzed the novel anticancer drugs approved in the United States (US) …

Patent and regulatory exclusivity shall constitute incentives for pharmaceutical companies to
develop new drugs. This study aims to investigate the differences in the patent term …

China has been criticized for the long drug delay for a long time. There was little
understanding of Chinese drug lag formation from the investigational new drug (IND) …

Immune checkpoint inhibitors (ICIs) are currently one of the most popular treatment methods
for cancers. Several ICIs have been approved in China and the United States. We created a …

Background In the past decade, the Chinese drug regulatory system has undergone many
changes. A major reform starting in 2015 has significantly reshaped the regulatory …

Cancer is a growing public health problem in China. Despite the high unmet medical need
of patients with cancer in China, oncology drug approvals have historically lagged behind …

Background To depict a comprehensive changing landscape of anti-lymphoma drug clinical
trials in mainland China from 2005 to 2020. Methods A systematic review was conducted on …

Challenges in anticancer drug R&D in China Challenges in anticancer drug R&D in China
Lancet Oncol. 2019 Feb;20(2):183-186. doi: 10.1016/S1470-2045(18)30865-9. Authors …